<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00816829</url>
  </required_header>
  <id_info>
    <org_study_id>C LF178P 05 01</org_study_id>
    <secondary_id>2005-000548-98</secondary_id>
    <nct_id>NCT00816829</nct_id>
  </id_info>
  <brief_title>Effect of Fenofibrate on Sleep Apnea Syndrome</brief_title>
  <official_title>A 1-month, Randomized, Double-blind, Placebo-controlled Study of Fenofibrate 145 mg Tablet in Patients With Sleep Apnea Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Solvay Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Solvay Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives: to investigate for the potential effect of fenofibrate on symptoms and biological
      changes associated with sleep apnea syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was prematurely terminated because of slow recruitment
  </why_stopped>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Obstructive Apneas</measure>
    <time_frame>at one month of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Desaturations</measure>
    <time_frame>at one month of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Sleep Time With Oxygen Saturation Below 90%</measure>
    <time_frame>at one month of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apneas</measure>
    <time_frame>at one month of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Hypopneas</measure>
    <time_frame>at one month of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Index Apnea/Hypopnea</measure>
    <time_frame>at one month of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mixed Apneas</measure>
    <time_frame>at one month of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Central Apneas</measure>
    <time_frame>at one month of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Index of Apneas</measure>
    <time_frame>at one month of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Index of Hypopneas</measure>
    <time_frame>at one month of treatment</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Dyslipidemia</condition>
  <condition>Sleep Apnea Syndrome</condition>
  <condition>Overweight</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Fenofibrate-matching placebo tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>145 mg NanoCrystal fenofibrate tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Fenofibrate-matching placebo tablet</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fenofibrate</intervention_name>
    <description>145 mg NanoCrystal tablet</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Having previous diagnosis of sleep apnea not treated with Continuous Positive Airway
             Pressure (CPAP) or presenting clinical symptoms of sleep apnea

          -  Overweight or obese, with BMI &gt;= 25 kg/m² and &lt; 40 kg/m².

          -  Known moderate hypertriglyceridemia, with fasting Triglycerides level &gt;= 2.0 and &lt; 6.0
             mmol/L within 3 months before the inclusion.

        Exclusion Criteria:

          -  indication for immediate CPAP

          -  other known endocrine disease, except treated and adequately controlled hypothyroidism

          -  renal failure or plasma creatinine level &gt;130 µmol/L

          -  current chronic liver disease or ALanine Amino Transferase (ALT)&gt; 2 times the upper
             normal limit (UNL)

          -  symptomatic gallbladder disease

          -  known muscular disease or creatine phosphokinase (CK) &gt; 3 times UNL.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Director Solvay</last_name>
    <role>Study Director</role>
    <affiliation>Solvay Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site 1</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 2, 2009</study_first_submitted>
  <study_first_submitted_qc>January 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2009</study_first_posted>
  <results_first_submitted>January 8, 2009</results_first_submitted>
  <results_first_submitted_qc>May 25, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 7, 2009</results_first_posted>
  <last_update_submitted>July 17, 2009</last_update_submitted>
  <last_update_submitted_qc>July 17, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2009</last_update_posted>
  <responsible_party>
    <name_title>Jean-Claude Ansquer</name_title>
    <organization>Solvay Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Dyslipidemia</keyword>
  <keyword>Sleep Apnea Syndromes</keyword>
  <keyword>Fenofibrate</keyword>
  <keyword>Obese</keyword>
  <keyword>Overweight or obese patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Overweight</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited and treated in a hospital in Paris between September 2005 and January 2008</recruitment_details>
      <pre_assignment_details>In total 34 subjects were randomly allocated to treatment (i.e. Subjects Started). All the subjects received the study drug and completed the study. The study was prematurely terminated because of low recruitment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
        <group group_id="P2">
          <title>Fenofibrate</title>
          <description>Fenofibrate 145 mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
        <group group_id="B2">
          <title>Fenofibrate</title>
          <description>Fenofibrate 145 mg</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.2" spread="6.5"/>
                    <measurement group_id="B2" value="55.9" spread="5.4"/>
                    <measurement group_id="B3" value="55.6" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Obstructive Apneas</title>
        <description>Total number of obstructive apneas during sleep during one night after one month of treatment (i.e. an occlusion of the airways accompanied by ineffective respiratory efforts).</description>
        <time_frame>at one month of treatment</time_frame>
        <population>The analysis was performed using the total sample of randomized subjects (16 on placebo and 18 on fenofibrate).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Fenofibrate</title>
            <description>Fenofibrate 145 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Obstructive Apneas</title>
          <description>Total number of obstructive apneas during sleep during one night after one month of treatment (i.e. an occlusion of the airways accompanied by ineffective respiratory efforts).</description>
          <population>The analysis was performed using the total sample of randomized subjects (16 on placebo and 18 on fenofibrate).</population>
          <units>Number of obstructive apneas</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.5" lower_limit="0" upper_limit="318"/>
                    <measurement group_id="O2" value="15.0" lower_limit="0" upper_limit="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between groups was performed using an ANCOVA on log-transformed data at one month after the start of the treatment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.048</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Desaturations</title>
        <description>Total number of desaturation events (i.e. defined as a decrease by 3 - 4% in oxygen saturation) during sleep during one night after one month of treatment.</description>
        <time_frame>at one month of treatment</time_frame>
        <population>The analysis was performed on the total sample of randomized subjects (16 on placebo and 18 in fenofibrate).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Fenofibrate</title>
            <description>Fenofibrate 145 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Desaturations</title>
          <description>Total number of desaturation events (i.e. defined as a decrease by 3 - 4% in oxygen saturation) during sleep during one night after one month of treatment.</description>
          <population>The analysis was performed on the total sample of randomized subjects (16 on placebo and 18 in fenofibrate).</population>
          <units>Number of desaturations</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171.0" lower_limit="61.0" upper_limit="674.0"/>
                    <measurement group_id="O2" value="130.0" lower_limit="14.0" upper_limit="219.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between groups was performed using an ANCOVA on log-transformed data at one month after the start of the treatment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.203</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Sleep Time With Oxygen Saturation Below 90%</title>
        <description>Percentage of Sleep time with oxygen saturation below 90% (measured by oximetry). Marker of consequences of apneas/hypopneas on arterial oxygenation during sleep during one night after one month of treatment. Higher percentage are worst for the patients.</description>
        <time_frame>at one month of treatment</time_frame>
        <population>The analysis was performed on the total sample of randomized subjects (16 on placebo and 18 on fenofibrate).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Fenofibrate</title>
            <description>Fenofibrate 145 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Time With Oxygen Saturation Below 90%</title>
          <description>Percentage of Sleep time with oxygen saturation below 90% (measured by oximetry). Marker of consequences of apneas/hypopneas on arterial oxygenation during sleep during one night after one month of treatment. Higher percentage are worst for the patients.</description>
          <population>The analysis was performed on the total sample of randomized subjects (16 on placebo and 18 on fenofibrate).</population>
          <units>Percentage of sleep time</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" lower_limit="3.0" upper_limit="60.0"/>
                    <measurement group_id="O2" value="3.5" lower_limit="0.0" upper_limit="49.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between groups was performed using Wilcoxon Test on data at one month after the start of the treatment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apneas</title>
        <description>Total number of episodes of apneas (i.e. cessation of breathing for at least 10 seconds) from central, obstructive or mixed origin during sleep during one night after one month of treatment</description>
        <time_frame>at one month of treatment</time_frame>
        <population>The analysis was performed on the total sample of randomized subjects (16 on placebo and 18 on fenofibrate).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Fenofibrate</title>
            <description>Fenofibrate 145 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Apneas</title>
          <description>Total number of episodes of apneas (i.e. cessation of breathing for at least 10 seconds) from central, obstructive or mixed origin during sleep during one night after one month of treatment</description>
          <population>The analysis was performed on the total sample of randomized subjects (16 on placebo and 18 on fenofibrate).</population>
          <units>Number of apneas</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.0" lower_limit="0" upper_limit="617"/>
                    <measurement group_id="O2" value="20.5" lower_limit="0" upper_limit="268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between groups was performed using an ANCOVA on log-transformed data at one month after the start of the treatment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.199</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hypopneas</title>
        <description>Total number of episodes of hypopneas (i.e. 50% to 80% reduction in airflow with a decrease of 3-4% in arterial oxygen saturation) during sleep during one night after one month of treatment.</description>
        <time_frame>at one month of treatment</time_frame>
        <population>The analysis was performed on the total sample of randomized subjects (16 on placebo and 18 on fenofibrate).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Fenofibrate</title>
            <description>Fenofibrate 145 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Hypopneas</title>
          <description>Total number of episodes of hypopneas (i.e. 50% to 80% reduction in airflow with a decrease of 3-4% in arterial oxygen saturation) during sleep during one night after one month of treatment.</description>
          <population>The analysis was performed on the total sample of randomized subjects (16 on placebo and 18 on fenofibrate).</population>
          <units>Number of hypopneas</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.5" lower_limit="32.0" upper_limit="222.0"/>
                    <measurement group_id="O2" value="63.0" lower_limit="1.0" upper_limit="179.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between groups was performed using an ANCOVA on log-transformed data at one month after the start of the treatment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.114</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Index Apnea/Hypopnea</title>
        <description>Average number of apneas and/or hypopneas per hour of sleep during one night after one month of treatment.</description>
        <time_frame>at one month of treatment</time_frame>
        <population>The analysis was performed on the total sample of randomized subjects (16 on placebo and 18 on fenofibrate).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Fenofibrate</title>
            <description>Fenofibrate 145 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Index Apnea/Hypopnea</title>
          <description>Average number of apneas and/or hypopneas per hour of sleep during one night after one month of treatment.</description>
          <population>The analysis was performed on the total sample of randomized subjects (16 on placebo and 18 on fenofibrate).</population>
          <units>Number per hour of sleep</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.5" lower_limit="4.0" upper_limit="114.0"/>
                    <measurement group_id="O2" value="17.0" lower_limit="0" upper_limit="47.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between groups was performed using an ANCOVA on log-transformed data at one month after the start of the treatment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.533</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mixed Apneas</title>
        <description>Total number of mixed apneas (i.e. sleep apneas that have both obstructive and central component) during sleep during one night after one month of treatment.</description>
        <time_frame>at one month of treatment</time_frame>
        <population>The analysis was performed on the total sample of randomized subjects (16 on placebo and 18 on fenofibrate).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Fenofibrate</title>
            <description>Fenofibrate 145 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Mixed Apneas</title>
          <description>Total number of mixed apneas (i.e. sleep apneas that have both obstructive and central component) during sleep during one night after one month of treatment.</description>
          <population>The analysis was performed on the total sample of randomized subjects (16 on placebo and 18 on fenofibrate).</population>
          <units>Number of mixed apneas</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="220.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.0" upper_limit="28.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between groups was performed using an ANCOVA on log-transformed data at one month after the start of the treatment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.521</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Central Apneas</title>
        <description>Total number of central apneas (i.e. apneas with no respiratory effort present) during sleep during one night after one month of treatment.</description>
        <time_frame>at one month of treatment</time_frame>
        <population>The analysis was performed on the total sample of randomized subjects (16 on placebo and 18 on fenofibrate).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Fenofibrate</title>
            <description>Fenofibrate 145 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Central Apneas</title>
          <description>Total number of central apneas (i.e. apneas with no respiratory effort present) during sleep during one night after one month of treatment.</description>
          <population>The analysis was performed on the total sample of randomized subjects (16 on placebo and 18 on fenofibrate).</population>
          <units>Number of central apneas</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="68.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.0" upper_limit="46.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between groups was performed using an ANCOVA on log-transformed data at one month after the start of the treatment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.333</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Index of Apneas</title>
        <description>Average number of apneas per hour of sleep during one night after one month of treatment.</description>
        <time_frame>at one month of treatment</time_frame>
        <population>The analysis was performed on the total sample of randomized subjects (16 on placebo and 18 on fenofibrate).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Fenofibrate</title>
            <description>Fenofibrate 145 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Index of Apneas</title>
          <description>Average number of apneas per hour of sleep during one night after one month of treatment.</description>
          <population>The analysis was performed on the total sample of randomized subjects (16 on placebo and 18 on fenofibrate).</population>
          <units>Number per hour of sleep</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="0.0" upper_limit="105.0"/>
                    <measurement group_id="O2" value="2.5" lower_limit="0.0" upper_limit="45.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between groups was performed using an ANCOVA on log-transformed data at one month after the start of the treatment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.264</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Index of Hypopneas</title>
        <description>Average number of hypopneas per hour of sleep during one night after one month of treatment.</description>
        <time_frame>at one month of treatment</time_frame>
        <population>The analysis was performed on the total sample of randomized subjects (16 on placebo and 18 on fenofibrate).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Fenofibrate</title>
            <description>Fenofibrate 145 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Index of Hypopneas</title>
          <description>Average number of hypopneas per hour of sleep during one night after one month of treatment.</description>
          <population>The analysis was performed on the total sample of randomized subjects (16 on placebo and 18 on fenofibrate).</population>
          <units>Number per hour of sleep</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0" lower_limit="4.0" upper_limit="31.0"/>
                    <measurement group_id="O2" value="9.5" lower_limit="0.0" upper_limit="33.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between groups was performed using an ANCOVA on log-transformed data at one month after the start of the treatment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.401</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
        <group group_id="E2">
          <title>Fenofibrate</title>
          <description>Fenofibrate 145 mg</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0"/>
                <counts group_id="E2" subjects_affected="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Metabolic and medical procedures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>6.6</frequency_threshold>
        <default_vocab>MedDRA 10.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1"/>
                <counts group_id="E2" subjects_affected="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus non-insulin-dependent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinitis Allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Only treatment emergent events have been presented. They are defined as events started at or after the 1st administration of study medication and includes events started prior to the 1st administration but which worsened after the 1st intake.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Sven Voet, Global Communication</name_or_title>
      <organization>Solvay Pharmaceuticals</organization>
      <phone>+32 (0) 2 509 69 77</phone>
      <email>sven.voet@solvay.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

